Development and validation of a new method for the quantification of norfloxacin by HPLC-UV and its application to a comparative pharmacokinetic study in human volunteers

Danilo César Galindo Bedor¹, Talita Mota Gonçalves¹, Leila Leal Bastos¹, Carlos Eduardo Miranda de Sousa¹, Luis Renato Pires de Abreu¹, Eduardo de Jesus Oliveira², Davi Pereira de Santana¹*

¹ Núcleo de Desenvolvimento Farmacêutico e Cosmético, Universidade Federal de Pernambuco, NUDFAC/UFPE, ² Laboratório de Tecnologia Farmacêutica, Universidade Federal da Paraíba

The development and validation of a simple and accurate method based on HPLC with ultraviolet detection for the quantification of norfloxacin (NFX) in human plasma and its application to a bioequivalence study between two norfloxacin formulations is described. NFX and the internal standard (ciprofloxacin) were extracted from plasma using liquid-liquid extraction. Chromatographic separation of norfloxacin, ciprofloxacin and plasma interferents was achieved with a C-18 column and a mobile phase consisting of 20 mM sodium hydrogen phosphate buffer pH 3.0 and acetonitrile (88:12, v/v) and quantitation was done at 280 nm. The method was linear from 25 to 3000 ng mL⁻¹ (r² ≥ 0.997578), and norfloxacin and ciprofloxacin had an average recovery from plasma of 93.9% and 91.2% respectively. The RSD of inter-day quality control samples at the lower limit of quantification was less than 15%. After a single oral dose (400 mg) of norfloxacin administered to healthy human volunteers using a randomized 2x2 crossover design, pharmacokinetic parameters (AUC₀-ₜ, AUC₀-∞, Cmax, t½) were derived from the plasma concentration curves for both formulations. Pharmacokinetic analysis of the data showed that the two formulations were bioequivalent, while no adverse reactions to the drug were observed.

INTRODUCTION

Norfloxacin (1-ethyl-fluoro-1,4-dihydro-4-oxo-7(1-piperaziny)-3-quinoline carboxylic acid) (Figure 1) is a large spectrum synthetic fluoroquinolone antibiotic which is structurally related to nalidixic acid (Córdoba-Borrego et al., 1999) (Figure 2). The addition of a fluorine atom at C-6 and a piperazine ring at C-7 has increased its potency in relation to other fluoroquinolones (Espinosa-Mansilla et al., 2006). Norfloxacin is synthesized by heating 1-ethyl-6-fluor-7chloro-1,4-dihydro-4-oxoquinoline-3carboxylic
Norfloxacin solutions are photosensitive to sunlight and to fluorescent light (Córdoba-Borrego et al., 1999).

Norfloxacin is well tolerated and widely used against both gram-positive and gram-negative infections, including Neisseria gonorrhoeae, gentamycin-resistant Pseudomonas aeruginosa, Haemophilus influenzae, and methicillin-resistant Staphylococcus aureus (Córdoba-Borrego et al., 1999; Rao, Nagaraju, 2004; Lim et al., 2002). It is mainly used in the treatment of urinary, respiratory and gastrointestinal tract infections (Rao, Nagaraju, 2004).

Norfloxacin is rapidly absorbed after oral administration (with 35 to 40% oral bioavailability). After an oral dose of 400 mg, plasma peak concentration (around 1.60 µg/mL) is achieved within 3 hours. Plasma half-life is 5 hours (Farinotti, 1991). Approximately 30% of the administered dose is eliminated unaltered by the kidneys, producing high concentrations in urine (Vilchez et al., 2001). Indeed, norfloxacin is frequently used to treat urinary infections with a 400 mg dose twice-daily regimen (Mascher, Kikuta, 1998).

High performance liquid chromatography methods have been used in the determination of norfloxacin in biological fluids and in pharmaceutical dosage forms (Carlucci, 1998). There are several methods in the literature for norfloxacin quantification in human plasma and in animal tissues employing different extraction and detection strategies. Amongst those are liquid-liquid extraction with ultraviolet detection (Wallis et al., 1995), and protein precipitation with UV (Samanidou et al., 2003) or fluorescence detection (Well et al., 1998). More recent methods include liquid chromatography coupled to mass spectrometry detection (Toussaint et al., 2002; Ballesteros et al., 2003). Although these methods are suitable for the determination of norfloxacin in plasma, the limit of quantification of the UV-based methods is around 100 ng mL⁻¹. While mass spectrometry provides a much higher sensitivity, the technique is not available to many laboratories. Thus, in order to accurately represent the elimination phase of the plasma-concentration-versus-time curve, we developed a simple and accurate method based on HPLC with UV detection and a lower limit of quantification of 25 ng mL⁻¹.

The method was developed, validated and applied to the bioequivalence study of two 400 mg tablets of norfloxacin. The study involved a single oral dose of 400 mg of norfloxacin in an open, randomized, 2x2 crossover design using 26 healthy volunteers aged 18-45 years (22.8 average) and a washout period of 7 days.

**MATERIAL AND METHODS**

**Chemicals**

Norfloxacin reference standard was acquired from the Instituto Nacional de Controle de Qualidade em Saúde (INCQS, Rio de Janeiro, Brazil) and ciprofloxacin (internal standard) from the United States Pharmacopea (Rockville, MD, EUA). HPLC-grade methanol and acetonitrile was purchased from J.T. Baker (Phillipsburg, NJ, EUA) and chloroform from Merck (Darmstadt, Germany). Sodium hydrogen phosphate and phosphoric acid were from Sigma-Aldrich (St. Louis, MO, EUA). Water was purified using a MilliQ® system from Millipore (Molsheim, France). Floxacin® (Merck Sharp & Dhome) and the test formulation (400 mg tablets) were purchased from the local pharmacy.

**Equipment**

High performance liquid chromatography was done using a chromatograph composed of two pumps (LC 10ADvp), a column oven (CTO 10Avp), a UV/VIS detector (SPD 10AVvp) configured to acquire data at 280 nm, an autosampler (SIL 10ADvp), and a system controller (SCL 10Avp) all from Shimadzu (Kyoto, Japão). For sample extraction a Jouan M23i refrigerated centrifuge (St.
Herblaim, França) was used. Samples were stored at a -70 °C REVCO (Asheville, NC, EUA) freezer until analysis.

**Chromatography**

Chromatographic separation was achieved using a Gemini® C18 column (Phenomenex, Torrance, CA, EUA) with 150 x 4.6 mm and 5 µm particle size coupled to a C18 4.0 x 3.0 mm precolumn (also from Phenomenex). The mobile phase consisted of 20 mM sodium hydrogen phosphate buffer (adjusted to pH 3.0 with phosphoric acid) and acetonitrile (88:12, v/v) which was filtered, degassed and pumped at a flow rate of 1.2 mL/min. The column oven was set at 40 °C and the injected volume was 50 µL. Quantitation of norfloxacin was done by measuring the response (area) of norfloxacin in relation to the response of ciprofloxacin (internal standard).

**Sample preparation**

**Preparation of working solutions and quality control standards**

The stock solutions of norfloxacin (at 1.0 mg mL⁻¹) were prepared by dissolving the substance in methanol:water (1:1 v/v) acidified with 30 µL of formic acid and the internal standard stock solution (at 1.0 mg.mL⁻¹) was prepared in methanol:water (1:1 v/v). The working solutions of norfloxacin were prepared in mobile phase (see chromatography above) to cover a range of concentrations from 25 to 3000 ng mL⁻¹. The internal standard working solution was also prepared in mobile phase at a concentration of 4000 ng mL⁻¹. The calibration curves for norfloxacin were prepared in human plasma at concentrations of 25, 50, 100, 300, 600, 1000, 1500, 2500 e 3000 ng mL⁻¹. Quality control samples were also prepared in human plasma at the following concentrations: 150, 1200 e 2250 ng mL⁻¹ (low, medium and high quality controls respectively). All calibration samples were prepared by adding 100 µL of norfloxacin stock solution to 9900 µL of human plasma, taken from a pool of 6 volunteers. The concentration of norfloxacin stock solution used was adjusted to give upon dilution (10x dilution) the concentration required by the calibration sample to be prepared.

**Sample preparation**

Plasma samples (250 µL) were transferred to a 2 mL polypropylene vial to which internal standard (50 µL, 4000 ng mL⁻¹) and 1 mL of chloroform was added. The samples were centrifuged at 10,000 rpm for 1 minute. The vials were then frozen and the aqueous layer discarded. The organic phase was transferred to 2 mL glass vials and the solvent was evaporated to dryness at 40 °C under a stream of nitrogen. The residue was redissolved in 250 µL of mobile phase, of which 200 µL was transferred into 250 µL glass vials and placed in the autosampler for analysis. The injection volume was 50 µL. Sample vials were wrapped in aluminium foil to protect norfloxacin from light exposure.

**Clinical Protocol**

The bioequivalence study was conducted in 26 volunteers from 18 to 45 years (average of 22.8 years old), with an average weight of 69.26 kg (body mass index around 15% of ideal). The volunteers were submitted to an evaluation including anamnesis, psychological tests, electrocardiogram, and laboratory tests (hematological, serological and biochemical tests) four weeks before the beginning of the study. All volunteers were required to sign an informed consent form, and the clinical protocol had the approval of the Ethics Committee of Federal University of Pernambuco (Protocol number 066/2005). The volunteers were hospitalized in two occasions separated by a washout period of 7 days. At each period the volunteers (randomly assigned to the test or reference formulation) received in fasted state a single tablet of 400 mg of norfloxacin administered with the aid of 240 mL of water. After 4 hours the volunteers received a standard meal. The 16 blood samples were collected by a heparinized butterfly at 0.0, 0.5, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 14.0, 18.0 e 24.0 hours after dosing. At each time point, 8 mL of blood was withdrawn from the brachial vein and were transferred to glass containing EDTA. Blood samples were centrifuged at 2500 rpm and plasma was stored in polypropylene cryogenic tubes at -70 °C until analysis.

**Validation**

**Selectivity**

Selectivity was evaluated by extracting plasma samples from a pool of plasma, including a lipemic and hemolysed plasma. The absence of interfering peaks at the same retention time of analytes or internal standard was considered as evidence for selectivity.

**Linearity**

Calibration curves were constructed using linear regression (with concentration as 1/x) within the range of 25–3000 ng mL⁻¹ of norfloxacin.

**Recovery**

Recovery of analyte was evaluated by comparing the response of norfloxacin in each quality control samples...
(150, 1200 e 2250 ng mL⁻¹) with the response of norfloxacin in solutions prepared with the same nominal concentration. Recovery of internal standard was calculated in the same manner, but only at the working concentration (4000 ng mL⁻¹).

**Precision and accuracy**

For precision and accuracy studies, samples were prepared at 3 concentration levels (low, medium and high quality controls, corresponding to 150, 1200 e 2250 ng mL⁻¹ respectively) with 5 replicates each, and were analysed in the same day (intra-day precision and accuracy), or prepared and analysed in 3 consecutive days (inter-day precision and accuracy).

**Stability studies**

The stability of the solutions and plasma samples was also evaluated during method validation. Norfloxacin stock solutions were analysed at two concentration levels (low and high quality control, corresponding to 150 and 2250 ng mL⁻¹ respectively) both recently prepared or after 7 days stored at 4 °C. The stability of norfloxacin was also evaluated in post-extracted samples kept in the autosampler at room temperature (23 °C) for 6 or 24 hours, as well as in plasma samples kept at -70 °C for 62 days and after being submitted to 3 freeze-thawing cycles (24 hours each cycle). All samples described above were compared to freshly prepared norfloxacin samples at the same concentration level.

**Statistical analysis, pharmacokinetics parameters**

Maximum plasma concentration (C_max) and the time to reach it (T_max) were derived directly from plasma concentration-versus-time curves. The area under the concentration-versus-time curve from 0–24 h (AUC₀⁻₄) was derived using the trapezoidal rule. The elimination constant (Kₑ) was obtained using linear regression of the elimination phase data points and the plasma half-life (t₁/₂) was derived from the relation t₁/₂ = ln2.Kₑ⁻¹. The values of C_max and AUC₀⁻₄ were compared using parametric (ANOVA) and non-parametric (Wilcoxon) statistical analysis. Pharmacokinetics parameters and statistical analysis were calculated by noncompartmental pharmacokinetics modelling with the software WinNonlin®, version 5.0.1.

**Adverse events**

The volunteers were evaluated through clinical observation and monitoring of vital signs such as arterial pressure, body temperature and pulse rate at baseline and at the end of each period volunteers were interviewed regarding the potential presence of adverse events (AEs) during the study.

**RESULTS AND DISCUSSION**

**Chromatographic optimization**

HPLC linked with photodiode array ultraviolet detector (DAD) has proven to be an important tool in the identification of compounds (Alabdalla, 2005). In our case the DAD was used for the selection of the best wavelength (280 nm) to maximize the signal of compounds and minimize the signal of plasma interferents. The chromatography conditions, especially the composition of mobile phase were optimized through several trials to achieve good resolution and symmetric peak shape for the analytes and I.S. The composition of the mobile phase was optimized by varying the percentage and pH of the sodium hydrogen phosphate buffer and percentages and type of organic component (Methanol or Acetonitrile). Finally 20 mM sodium monobasic phosphate pH 3.0: acetonitrile (88:12, v/v) was chosen as the final mobile phase since it provided the best separation, with higher sensitivity and selectivity for the UV signal of analytic and internal standard.

**Sample preparation**

The liquid liquid extraction procedure was developed by evaluating solvents of different polarity (diethyl ether, chloroform, ethyl acetate and dimethylsulfoxide), the ratio of sample to solvent volume and pH. Except for chloroform, all the others solvents evaluated resulted in recovery rates lower than 60%. The pH control of the extraction solution did not significantly interfered with the recovery of the analyte. Thus chloroform (1.0 mL) was chosen as the extraction solvent for sample preparation using 250 µL of human plasma.

**Selectivity**

The described method used reversed-phase HPLC for separation of norfloxacin from ciprofloxacin (internal standard) and was shown to be selective for the analyte and its internal standard (retention times for norfloxacin and ciprofloxacin were 10.5 e 12.4 min respectively). No interfering peaks were observed with the same retention time of the analytes when plasma samples (including lipemic and hemolysed ones) from different volunteers were analysed (Figure 3).
Development and validation of a new method for the quantification of norfloxacin by HPLC-UV

Linearity

Linearity was demonstrated from 25 – 3000 ng mL\(^{-1}\). Table I show data from calibration curves prepared in different days throughout the application of the method.

Each point was analysed in triplicate. The average correlation coefficient was 0.9976. The lower limit of quantification was determined to be 25 ng mL\(^{-1}\), which improved the accuracy of estimation of AUC\(_{0-t}\) when compared to AUC\(_{0-\infty}\).

### Table I - The precision and accuracy of points of calibration curves

<table>
<thead>
<tr>
<th>Nominal value (ng mL(^{-1}))</th>
<th>Observed value (ng mL(^{-1})) (Average ± SD) (n=13)</th>
<th>Precision (%)</th>
<th>Accuracy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>25.17 ± 0.83</td>
<td>3.30</td>
<td>100.68</td>
</tr>
<tr>
<td>50</td>
<td>49.73 ± 0.33</td>
<td>0.67</td>
<td>99.50</td>
</tr>
<tr>
<td>100</td>
<td>99.16 ± 1.31</td>
<td>1.32</td>
<td>99.20</td>
</tr>
<tr>
<td>300</td>
<td>319.09 ± 22.83</td>
<td>7.15</td>
<td>106.40</td>
</tr>
<tr>
<td>600</td>
<td>600.99 ± 2.13</td>
<td>0.36</td>
<td>100.20</td>
</tr>
<tr>
<td>1500</td>
<td>1536.29 ± 61.42</td>
<td>4.00</td>
<td>102.40</td>
</tr>
<tr>
<td>2500</td>
<td>2427.58 ± 23.36</td>
<td>0.96</td>
<td>97.10</td>
</tr>
<tr>
<td>3000</td>
<td>2887.63 ± 73.63</td>
<td>2.55</td>
<td>96.30</td>
</tr>
</tbody>
</table>
The average recovery for norfloxacin in plasma was 82.34%, 93.97%, 97.25% (n=15) for the low, medium and high quality control samples respectively (150, 1200 e 2250 ng mL⁻¹), with an average of 91.19%. The average recovery of the internal standard was 93.91%, evaluated at 4.0 µg.mL⁻¹.

**Precision and accuracy**

The intraday and interday precision and accuracy of the method for each norfloxacin concentration level (150, 1200 e 2250 ng mL⁻¹) and for the lower limit of quantification (25 ng mL⁻¹) are presented in Table II. The relative standard deviation for the quality control samples and for the LLOQ were respectively 2.46, 1.47, 1.16 e 10.6% and accuracy was 105.1, 103.2, 108.9 and 108.6% respectively.

**Stability studies**

Norfloxacin stock solutions (1 mg mL⁻¹) remained stable when stored at 4 °C for 7 days or when stored at room temperature up to 24 hours. When stored at −70 °C for 62 days, spiked plasma samples of norfloxacin presented losses of 1.9 and 3.0% for concentrations of 150 and 2250 ng mL⁻¹ respectively, in the others stability studies (stock solutions, post-extracted samples and 3 freeze-thawing cycles) norfloxacin did not show evidence of significant degradation.

**Pharmacokinetic parameters**

Figure 4 shows the averaged plasma concentration-versus-time curves for norfloxacin after administration of the reference (Floxacina® Merck Sharp & Dhome, 400 mg tablets) and test formulations. Table III shows the pharmacokinetic parameter values for the two brands (test and reference) of 400 mg norfloxacin tablets.

**TABLE II - Inter- and Intra-day precision and accuracy for norfloxacin**

<table>
<thead>
<tr>
<th>Nominal value (ng mL⁻¹)</th>
<th>Intra-day (ng mL⁻¹) (n=5)</th>
<th>Inter-day (ng mL⁻¹) (n=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1 Average ± SD</td>
<td>Day 2 Average ± SD</td>
</tr>
<tr>
<td>25</td>
<td>27,191±1,16</td>
<td>27,721±1,22</td>
</tr>
<tr>
<td>150</td>
<td>160,285±4,85</td>
<td>157,615±5,96</td>
</tr>
<tr>
<td>1200</td>
<td>1238,441±18,25</td>
<td>1286,710±66,90</td>
</tr>
<tr>
<td>2250</td>
<td>2451,103±50,89</td>
<td>2449,544±69,39</td>
</tr>
</tbody>
</table>

**TABLE III - Pharmacokinetic parameter for test and reference formulations**

<table>
<thead>
<tr>
<th>Pharmacokinetic parameter</th>
<th>Test formulation mean (RSD)</th>
<th>Reference formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUCₜₐ₀ (ng/mL.h)</td>
<td>5532 (31.7%)</td>
<td>5285.79 (32.7%)</td>
</tr>
<tr>
<td>AUCₜₐₜ (ng/mL.h)</td>
<td>6029.12 (29.3%)</td>
<td>5961.32 (29.6%)</td>
</tr>
<tr>
<td>Cₘₐₓ (ng/mL)</td>
<td>1072.75 (33.6%)</td>
<td>1047.67 (33.6%)</td>
</tr>
<tr>
<td>Tₘₐₓ</td>
<td>1.79 (43.3%)</td>
<td>1.61 (49.5%)</td>
</tr>
<tr>
<td>T 1/2</td>
<td>5.38 (23.6%)</td>
<td>6.40 (42.4%)</td>
</tr>
<tr>
<td>Kₑₑ (h/h)</td>
<td>0.14 (27.3%)</td>
<td>0.12 (26.0%)</td>
</tr>
<tr>
<td>Cl/F (L/h)</td>
<td>72.8 (34.2%)</td>
<td>74.3 (36.8%)</td>
</tr>
</tbody>
</table>
The shortest confidence interval (90%) for the ratio of $C_{\text{max}}$ means was 85.36% (lower limit) and 111.69% (upper limit). Mean $C_{\text{max}}$ calculated by method of least squares for the reference drug was 89.60 and 89.29 for the test, resulting in a ratio ($C_{\text{max,test}}/C_{\text{max,reference}}$) of 97.64 and a test power of 86.50%.

The area under the concentration-time curve from zero time to the time of the last sample collection, $AUC_{(0-t)}$ had lower and upper shortest confidence limits (90%) of 85.02 and 106.50, respectively. The $AUC_{(0-t)}$ means calculated by method of least squares were 123.425 ng/mL.h for the reference drug and 122.709 ng/mL.h for the test drug resulting in a ratio (test/reference) of 95.15 % and a test power for $AUC_{(0-t)}$ of 94.69%.

When the area under the concentration-time curve from zero to infinite ($AUC_{0-\infty}$) was calculated, the lower and upper shortest confidence limits (90%) were 88.62 and 109.6, respectively. The mean $AUC_{0-\infty}$ calculated for the reference and test formulation by the least squares were 137.182 ng/mL.h and 136.950 ng/mL.h resulting in a ratio (test formulation/reference formulation) of 98.55 and a power of test of 94.41%.

Adverse events

No adverse effect was noticed during the period in which the volunteers were hospitalized and both formulations were well tolerated.

CONCLUSION

We described here the development of a new, selective, precise and accurate method for the quantification of norfloxacin in human plasma using HPLC with UV detection and liquid-liquid sample extraction which was applied to a bioequivalence study. Fluoroquinolones have been usually determined using fluorescence detection (Mascher, Kikuta, 1998; Well et al., 1998; Galaon et al., 2007). Although fluorescence detection is usually more sensitive than detection by UV, fluorescence detectors are not as widely available. Also, the limit of detection of a method is determined not only by detection technique but also by the effective clean-up of sample and minimization of band broadening by columns effects which can improve signal to noise ratio. The method reported here uses a simple and effective extraction technique with good and reproducible recovery and a limit of quantification of 25 ng mL$^{-1}$. The developed method is suitable for pharmacokinetic studies of norfloxacin with a lower limit of quantification of 25 ng mL$^{-1}$, which represents less than 2.5% of norfloxacin’s $C_{\text{max}}$, and thus can be applied to estimation of pharmacokinetic parameters which are dependable of data points from the elimination phase such as $AUC_{0-\infty}$. The method was applied to the analysis of more than 1200 samples with good accuracy and precision (less than 7% RSD). The study was able to demonstrate bioequivalence (comparison of $AUC_{0-t}$, $AUC_{0-\infty}$, $C_{\text{max}}$) between the two formulations with a 90% confidence interval. Ahead of the clinical observations carried through during and after the study no adverse effect was observed, showing a good tolerability to the both formulations.

ACKNOWLEDGEMENTS

The authors wish to thank CNPq/CAPES and ANVISA-DF for financial support. Our gratitude for Iram Mundim for technical support.

RESUMO

Desenvolvimento e validação de um método para quantificação de norfloxacino por cromatografia líquida de alta eficiência e aplicação a estudo de farmacocinética comparada em voluntários humanos

O desenvolvimento e validação de um método simples e preciso por CLAE-UV para quantificação de norfloxacino (NFX) em plasma humano e a sua aplicação a um estudo de bioequivalência entre duas formulações são descritos. NFX e o padrão interno (ciprofloxacino, PI) foram extraídos do plasma através de extração líquido-líquido. A separação cromatográfica do NFX, do PI e dos interferentes do plasma foi realizada com uma coluna C-18 e fase móvel composta de tampão fosfato de sódio 20 mM pH 3,0 e acetonitrila (88/12, v/v) e quantificado em 280 nm. A resposta do detector aos analitos mostrou-se linear entre 25 a 3000 ng mL$^{-1}$ ($r^2 \geq 0,997578$) e a recuperação média de NFX e PI foi de 93,9% e 91,2% respectivamente. O desvio padrão relativo de amostras analisadas ao nível do limite inferior de quantificação foi menor que 15%. Foi administrada uma dose de NFX (400 mg) por via oral a voluntários humanos em um estudo aberto, aleatório e cruzado 2x2 entre duas formulações. Os parâmetros farmacocinéticos ($AUC_{0-t}$, $AUC_{0-\infty}$, $C_{\text{max}}$, $T_{1/2}$) foram observados a partir da curva de concentração versus tempo. A análise farmacocinética mostrou que as duas formulações são bioequivalentes entre si. Nenhum efeito adverso foi observado.

UNITERMS: Norfloxacino. CLAE. Bioequivalência. Farmacocinética.
REFERENCES


Recebido para publicação em 19 de dezembro de 2006.
Aceito para publicação em 31 de maio de 2007.